Clinical-stage immuno-oncology company TapImmune, Inc. (NASDAQ: TPIV) this morning announced that its collaborators at the Mayo Clinic recently received a $3.7 million grant from the U.S. Department of Defense (DoD) to conduct a Phase 2 clinical study on the company’s HER2/neu-targeted T-cell vaccine. The DoD-funded study will evaluate women diagnosed with an early form of breast cancer called ductal carcinoma in situ (DCIS), and, if successful, could clear the way for TapImmune’s vaccine to replace standard surgery and chemotherapy by becoming part of a routine immunization schedule for preventing breast cancer in healthy women.
“This is our second T-cell vaccine candidate to be tested in a DoD-funded Phase 2 study to the Mayo Clinic, and it marks our expansion into a second breast cancer indication,” Dr. Glynn Wilson, chairman and CEO of TapImmune, stated in the news release. “In addition to ongoing and planned Phase 2 studies of our lead TPIV 200 vaccine for treating triple-negative breast cancer, this new study of our HER2neu vaccine in DCIS has the potential to validate our novel approach to establishing lasting immunity against breast cancer and precancerous lesions.” The study, which is expected to enroll 40-45 women with DCIS, is scheduled to begin in 2017 and will be led by Keith Knutson, Ph.D., Director of Discovery and Translational Labs Cancer Research Program at Mayo Clinic’s Florida campus.
To view the full press release, visit http://nnw.fm/M5eOs
About TapImmune, Inc.
TapImmune, Inc. is a leader in the immunotherapy of woman’s cancers advancing multiple Phase 2 and Phase 1b/2 clinical studies for the treatment of ovarian and breast cancer. The company’s peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient’s killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The company’s technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the company’s website at www.tapimmune.com for more details.
About NetworkNewsBreak
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
